3d • General discussion
The Low-Activity COMT Genotype and Dopamine
Among the most clinically consequential single-nucleotide polymorphisms encountered in integrative and functional medicine practice is the COMT Val158Met (rs4680) variant. Catechol-O-methyltransferase (COMT) is the principal enzyme responsible for the metabolic degradation of catecholamines—dopamine, norepinephrine, and epinephrine—particularly within the prefrontal cortex, where dopamine transporter density is relatively sparse.1,2
Individuals homozygous for the Met allele (Met/Met, sometimes termed the “worrier” genotype) carry a COMT enzyme variant with approximately three- to four-fold lower catalytic activity compared to Val/Val homozygotes.3,4 While this confers certain cognitive advantages—enhanced working memory and executive function under baseline, low-stress conditions—it simultaneously creates vulnerability to catecholaminergic excess during periods of psychological or physiological stress. The clinical consequence is a characteristic phenotype: hyperarousal, heightened anxiety, difficulty with emotional regulation, and pronounced susceptibility to insomnia and sleep disruption.5
This article examines the molecular biochemistry underlying impaired COMT-mediated dopamine clearance and synthesizes the current evidence for targeted mitigation strategies, from methylation cofactor optimization to dietary modification and pharmacogenomic considerations.
0
0 comments
The Low-Activity COMT Genotype and Dopamine
powered by
skool.com/root-cause-health-community-5719
Root Causes Wellness Hub supports interest in Root Cause Medicine using holistic, integrative, and functional medicine.
Suggested communities
Powered by